Oxford Ebola vaccine booster to enter clinical trials

A prime boost for a vaccine candidate is being investigated by Oxford University. The boost to the GlaxoSmithKline (GSK) Chimp Adenovirus type 3 Ebola vaccine candidate will enter phase 1 trials, Oxford University announced Wednesday.
Emergent BioSolutions has manufactured the boost candidate for use in this trial. The study will enroll 38 volunteers to determine efficacy of the boosting candidate, a modified vaccinia Ankara (MVA) Ebola Zaire.
"Production of the first ever batch of MVA for a clinical trial using a cell line is a milestone in the development of this important vaccine technology," Professor and Director of the Jenner Institute at Oxford University, Adrian Hill said. "This new process, which will allow very large scale production, will be of value not only for Ebola prevention, but also for a wide range of other disease indications including malaria and tuberculosis vaccination."
Six volunteers will receive the boosting candidate by itself and the remaining 32 will receive doses of both the GSK candidate and the MVA candidate.
"We believe there is benefit in exploring different approaches such as a prime-boost strategy as we continue to develop our ChAd3 Ebola candidate vaccine," GSK Chairman of Vaccines, Dr. Moncef Slaoui said. "This ChAd3 Ebola candidate vaccine has shown encouraging immune responses and an acceptable safety and reactogenicity profile in ongoing phase 1 trials to date. Together, these different trials will provide important information about the vaccine and its potential to help combat this or future Ebola outbreaks."